

Change in CEO Compensation for GWDN Index Companies, 2012 vs 2011

| Company Name | CEO Name | Year | Base Salary | % Change in CEO Base Salary, 2012 over 2011 | Bonus | Stock Award | Option Award | Change in Pension Value and Non-qualified Deferred Compensation Earnings | Non-equity Incentive Plan Awards | All Other Compensation | Total Compensation | % Change in Total CEO Compensation, 2012 over 2011 |
|---------------------------------------|------------------------------|------|-------------|---|-----------|-------------|--------------|--|----------------------------------|------------------------|--------------------|--|
| Accelrys | Max Carneccchia | 2012 | 429,450 | | N/A | 482,400 | 525,840 | N/A | 433,465 | 10,673 | 1,881,828 | |
| | | 2011 | 415,000 | 3.36% | N/A | 281,600 | 307,540 | N/A | 260,652 | 221,231 | 1,486,023 | 26.64% |
| Accelerate Diagnostics ⁽¹⁾ | Larry Mehren | 2012 | 28,767 | | N/A | N/A | 1,123,279 | N/A | N/A | N/A | 1,152,046 | |
| | | 2011 | 131,481 | | N/A | N/A | 97,171 | N/A | N/A | 749,000 | 977,652 | |
| Affymetrix | Thomas Geimer | 2012 | 165,000 | -2.97% | N/A | N/A | N/A | N/A | N/A | 75,000 | 240,000 | 787.37% |
| | | 2011 | 529,041 | | N/A | 115,750 | N/A | N/A | N/A | 12,500 | 657,291 | |
| Agilent | William Sullivan | 2012 | 248,077 | 53.11% | N/A | 1,409,100 | 1,081,110 | N/A | N/A | 1,548 | 2,739,935 | -76.01% |
| | | 2011 | 990,000 | | N/A | 3,859,183 | 4,007,791 | N/A | 1,247,808 | 30,935 | 10,135,717 | |
| Becton Dickinson | Vincent Forlenza | 2012 | 990,000 | 0.00% | N/A | 3,521,505 | 3,788,302 | N/A | 1,922,258 | 30,200 | 10,252,264 | -1.14% |
| | | 2011 | 900,000 | | N/A | 3,441,639 | 2,292,422 | 1,662,465 | 1,080,000 | 41,750 | 9,418,276 | |
| Bio-Rad | Norman Schwartz | 2012 | 725,000 | 19.44% | N/A | 1,393,622 | 1,434,250 | 709,038 | 723,077 | 33,867 | 5,018,854 | 87.66% |
| | | 2011 | 803,385 | | N/A | 1,404,282 | 1,780,847 | N/A | 516,175 | 16,064 | 4,520,753 | |
| Bruker | Frank Laukien | 2012 | 770,000 | 4.16% | N/A | 1,200,720 | 1,703,502 | N/A | 154,962 | 15,814 | 3,844,998 | 17.57% |
| | | 2011 | 444,129 | | N/A | 1,206,000 | N/A | N/A | 202,973 | 7,500 | 1,860,602 | |
| Cepheid | John Bishop | 2012 | 433,337 | 2.43% | N/A | N/A | 112,950 | N/A | 338,463 | 7,350 | 892,100 | 108.56% |
| | | 2011 | 577,211 | | N/A | 607,240 | 2,350,730 | N/A | 160,425 | 80,989 | 3,776,595 | |
| CombiMatrix | Judd Jessup (former CEO) | 2012 | 566,827 | 1.80% | N/A | 787,125 | 2,652,390 | N/A | 500,250 | 69,634 | 4,576,225 | -17.47% |
| | | 2011 | 421,615 | | N/A | N/A | N/A | N/A | N/A | N/A | 421,615 | |
| Danaher | Lawrence Culp | 2012 | 420,000 | 0.38% | N/A | N/A | N/A | N/A | N/A | N/A | 420,000 | 0.38% |
| | | 2011 | 1,117,778 | | N/A | 7,653,255 | 7,888,608 | 1,861 | 4,525,000 | 712,226 | 21,898,728 | |
| Exact Sciences | Kevin Conroy | 2012 | 1,117,778 | 0.00% | N/A | 7,678,268 | 7,382,003 | 2,300 | 4,750,000 | 722,068 | 21,652,417 | 1.14% |
| | | 2011 | 445,750 | | 269,340 | 1,103,425 | 872,100 | N/A | N/A | 17,000 | 2,707,615 | |
| Fluidigm | Gajus Worthington | 2012 | 418,750 | 6.06% | 251,550 | 635,613 | N/A | N/A | N/A | 16,500 | 1,322,413 | 104.75% |
| | | 2011 | 350,000 | | N/A | N/A | 827,917 | N/A | 175,000 | N/A | 1,352,917 | |
| GenMark Diagnostics | Hany Massarany | 2012 | 350,000 | 0.00% | N/A | N/A | 608,469 | N/A | 150,000 | N/A | 1,108,469 | 22.05% |
| | | 2011 | 443,077 | | N/A | 670,796 | N/A | N/A | 228,375 | 7,353 | 1,349,601 | |
| Genomic Health | Kim Popovits | 2012 | 335,769 | 24.22% | 215,330 | 698,119 | 697,622 | N/A | N/A | 81,466 | 2,028,306 | -33.46% |
| | | 2011 | 600,000 | | N/A | 289,700 | 1,254,386 | N/A | 234,000 | N/A | 2,144,086 | |
| Hologic | Robert Cascella | 2012 | 490,000 | 18.33% | N/A | 229,800 | 1,004,005 | N/A | 109,800 | N/A | 1,833,605 | 16.93% |
| | | 2011 | 899,727 | | N/A | 877,332 | 2,589,602 | N/A | 763,560 | 256,883 | 5,387,101 | |
| Illumina | Jay Flatley | 2012 | 885,403 | 1.59% | N/A | 749,987 | 2,246,615 | N/A | 902,187 | 1,254,107 | 6,038,299 | -10.78% |
| | | 2011 | 802,950 | | 200,000 | 6,288,207 | N/A | N/A | 862,935 | 16,988 | 8,171,080 | |
| Life Technologies | Greg Lucier | 2012 | 779,423 | 2.93% | N/A | 1,770,500 | 6,726,848 | N/A | 650,988 | 16,388 | 9,944,147 | -17.83% |
| | | 2011 | 1,200,000 | | N/A | 4,499,965 | 2,249,994 | N/A | 2,160,000 | 158,486 | 10,268,445 | |
| Luminex | Patrick Balthrop | 2012 | 1,186,539 | 1.12% | N/A | 7,999,948 | | N/A | 1,570,000 | 141,143 | 10,897,630 | -5.77% |
| | | 2011 | 653,737 | | N/A | 1,561,830 | 419,989 | N/A | 543,909 | 35,013 | 3,214,478 | |
| Myriad Genetics | Peter Meldrum | 2012 | 513,674 | 21.42% | N/A | 2,411,447 | 119,996 | N/A | 716,575 | 20,325 | 3,782,017 | -15.01% |
| | | 2011 | 915,812 | | 1,100,761 | N/A | 3,925,095 | N/A | N/A | 10,040 | 5,951,708 | |
| Nanosphere | William Moffitt (former CEO) | 2012 | 870,504 | 4.95% | 956,312 | N/A | 3,029,902 | N/A | N/A | 9,866 | 4,866,584 | 22.30% |
| | | 2011 | 457,885 | | N/A | N/A | N/A | N/A | N/A | N/A | 457,885 | |
| Pacific Biosciences ⁽²⁾ | Michael Hunkapiller | 2012 | 457,885 | 0.00% | N/A | N/A | 428,061 | N/A | N/A | N/A | 885,946 | -48.32% |
| | | 2011 | 394,102 | | N/A | N/A | 1,782,900 | N/A | N/A | N/A | 2,177,002 | |
| PerkinElmer | Hugh Martin (former CEO) | 2012 | 4,615 | | N/A | N/A | N/A | N/A | N/A | 390,000 | 304,615 | |
| | | 2011 | 300,000 | 24.76% | N/A | N/A | N/A | N/A | N/A | N/A | 300,000 | 727.21% |
| Sequenom | Robert Friel | 2012 | 951,923 | | N/A | 1,599,991 | 1,599,696 | 1,007,695 | 5,562,329 | 110,976 | 10,832,610 | |
| | | 2011 | 921,923 | 3.15% | N/A | 2,885,508 | 1,549,273 | 1,669,569 | 5,685,140 | 107,768 | 12,819,181 | -15.50% |
| Qiagen ⁽³⁾ | Peer Schatz | 2012 | 1,226,000 | | 168,000 | N/A | N/A | N/A | N/A | 5,000 | 1,399,000 | |
| | | 2011 | 1,305,000 | -6.44% | 539,000 | N/A | N/A | N/A | N/A | 1,000 | 1,845,000 | -24.17% |
| Sequenom | Harry Hixson | 2012 | 500,000 | | N/A | N/A | 1,557,147 | N/A | 303,900 | 6,986 | 2,368,033 | |
| | | 2011 | 489,250 | 2.15% | N/A | 260,625 | 2,079,400 | N/A | 318,000 | 6,884 | 3,154,159 | -24.92% |

| | | | | | | | | | | | | |
|--------------------------|------------------------|------|-------------------|--------------|--------|------------|-----------|---------|-----------|---------|--------------------|--------------|
| Sigma-Aldrich | Rakesh Sachdev | 2012 | 792,308 | | N/A | 1,577,620 | 1,446,120 | 10,856 | 656,800 | 101,718 | 4,585,422 | |
| | | 2011 | 700,000 | 11.65% | 63,800 | 1,032,462 | 1,116,896 | 9,397 | 886,200 | 106,774 | 3,915,529 | 17.11% |
| Thermo Fisher Scientific | Marc Casper | 2012 | 1,030,038 | | N/A | 10,442,400 | N/A | N/A | 1,892,800 | 189,863 | 13,555,101 | |
| | | 2011 | 1,000,000 | 2.92% | N/A | N/A | 3,064,050 | N/A | 1,300,000 | 152,517 | 5,516,567 | 145.72% |
| Vermillion | Gail Page (former CEO) | 2012 | 352,917 | | N/A | 258,884 | 168,837 | N/A | N/A | 508,855 | 1,289,493 | |
| | | 2011 | 385,000 | -9.09% | N/A | 1,085,946 | 76,726 | N/A | 57,750 | 22,281 | 1,627,703 | -20.78% |
| Waters | Douglas Berthiaume | 2012 | 814,776 | | N/A | N/A | N/A | 104,369 | | 143,827 | 1,062,972 | |
| | | 2011 | 794,903 | 2.44% | N/A | N/A | N/A | 150,965 | 1,562,840 | 138,022 | 2,646,730 | -59.84% |
| Total 2012 | | | 19,208,474 | | | | | | | | 135,280,267 | |
| Total 2011 | | | 18,035,042 | 6.11% | | | | | | | 125,655,101 | 7.66% |

⁽¹⁾ Both Larry Mehren and Thomas Geimer's 2012 compensation were used to determine the percentage increase in base salary and total compensation for 2012 over 2011

⁽²⁾ Both Michael Hunkapiller and Hugh Martin's 2012 compensation were used to determine the percentage increase in base salary and total compensation for 2012 over 2011.

⁽³⁾ Qiagen reported Peer Schatz's stock options and other benefits in units, not dollars.